imatinib

Home/Tag: imatinib

Survival in Advanced GIST Has Improved Over Time – LRG Science

In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.

By |2020-05-01T10:01:32-04:00April 1st, 2020|Drug Treatment, LRG Science, News, Research|

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2020-05-01T09:56:32-04:00December 13th, 2019|Drug Treatment, Gleevec, LRG Science, News|

New Data Indicates Imatinib Boosts Long-Term Survival for Some GIST Patients

A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]

By |2018-10-30T09:19:32-04:00February 27th, 2017|News, Research|

Study Highlights Role of ABL1 in GIST Treated with Imatinib

A recent study published in Oncotarget, discussed the potential role of the kinase, ABL1 as a potential impediment to anti-tumor processes in GIST treated with imatinib mesylate. The Life Raft Group’s Research Team member, [...]

By |2018-10-30T09:23:31-04:00January 19th, 2017|News, Research|

Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By |2020-07-09T16:00:18-04:00September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

Study Finds Adjuvant Systemic Therapy with Imatinib Increasing Over Time

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]

By |2018-10-30T09:55:33-04:00March 15th, 2016|Drug Treatment, News, Survival Strategies|

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.

By |2019-09-23T11:28:24-04:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-04:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|
Go to Top